Showing results (41-50 of 84) with videos related to
Sort By:
Pageof 9
Bulletin Du Cancer|January 1, 1992
[Role of neoadjuvant chemotherapy in the treatment of advanced head and neck tumors. Results of two randomized therapeutical trials conducted at the Institut Curie on 208 patients]F Brunin, J Rodriguez, C Jaulerry, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1995
Contralateral breast cancer: annual incidence and risk parametersP Broët, A de la Rochefordière, S M Scholl, et al.Bulletin Du Cancer|January 1, 1989
[Metastatic breast cancer. Chemotherapy with adriamycin, vindesine, cyclophosphamide and 5 FU. Value of continuous 5 FU perfusion. Results of controlled trials]M Jouve, T Palangie, L Belli, et al.International Journal of Radiation Oncology, Biology, Physics|September 30, 1995
Prognostic value of tumor regression during radiotherapy for head and neck cancer: a prospective studyC Jaulerry, B Dubray, F Brunin, et al.British Journal of Cancer|May 1, 1994
Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patientsE Tartour, T Dorval, V Mosseri, et al.International Journal of Cancer|April 22, 1996
Clinical relevance of loss heterozygosity of the short arm of chromosome 1 in neuroblastoma: a single-institution studyG Schleiermacher, O Delattre, M Peter, et al.British Journal of Cancer|December 4, 2003
Anal canal cancer treatment: practical limitations of routine prescription of concurrent chemotherapy and radiotherapyL Chauveinc, X Buthaud, M C Falcou, et al.European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Prognostic factors in inflammatory breast cancer and therapeutic implicationsT Palangie, V Mosseri, J Mihura, et al.Cancer|April 1, 1997
Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma: results of a multivariate prospective studyE Tartour, L Deneux, V Mosseri, et al.Immunology Letters|July 1, 1997
IL-6 is a survival prognostic factor in renal cell carcinomaN Thiounn, F Pages, T Flam, et al.Pageof 9